I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several key announcements that signal a strategic shift in the company's leadership and research focus.

The company revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This committee, which also includes Dr. Cao and CEO Dr. Sean Fu, is designed to accelerate innovation and long-term growth at I-Mab.

In addition to the board appointments, I-Mab announced the expansion of its Scientific Advisory Board with the addition of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These strategic moves are seen as bolstering I-Mab's expertise in R&D and immuno-oncology, particularly as the company progresses with its lead candidate, givastomig, a potential best-in-class bispecific antibody for gastric cancers. Investors appear to be reacting positively to these developments, viewing them as potential catalysts for the company's future growth and scientific advancements in the competitive biotech landscape.